3Rosenberg SA, Lotze MT, Muul LM. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone[J]. N Engl J Med,1987,316:889 -897.
4Rosenberg SA, Lotze MT, Yang JC, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer[J]. J Nail Cancer Inst,1993,85:622-632.
5Rosenberg SA, Yannclli JR, Yang JC, et al. Treatment of patients with metastatic melanoma with autologous tumor-in.'? ltrating lymphoeytes and interleukin 2 [ J ]. J Natl Cancer Inst, 1994,86 : 1159-1166.
6Aebersold P, Hyatt C, Johnson S, et al. Lysis of autologous melanoma ceils by tumor-in? ltrating lymphocytes : association with clinical response[J]. J Natl Cancer Inst,1991,83 :932 -937.
7Ichim CV. Revisiting Implications for cancer immunotherapy [ J ] 8. and immunostimulation : J Transl Med ,2005,3 :8.
8Marleau AM, Sarvetnick N. T cell homeostasis in tolerance and immunity[ J]. J Leukoc Biol,2005,78:575-584.
9Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes [ J ]. Science,2002,298 : 850-854.
10Khayat D, Bernard-Marty C, Meric JB, el al. Biochemotherapy for advanced melanoma: maybe it is real [ J ]. J Clin Oncol, 2002,20 (10) :2411.
